Camlin Fine Sciences Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Camlin Fine Sciences Ltd trades at ₹123, in a downtrend and 36 weeks into that stage. That is −15.8% against its own 200-day average. It sits at 16% of a 52-week range of ₹103 to ₹230. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).

Today the stock is in a downtrend — week 36 of stage 4, confirmed. At ₹123 it trades −15.8% versus its 200-day average and sits at 16% of its 52-week range (₹103–₹230).

Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +33% while the NIFTY 500 moved +274% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-07-03) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 76th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Camlin Fine Sciences Ltd trades at 65.6× P/E, at the pricey end of its own range (76th percentile). Its long-run median P/E is 45.9×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 65.6× is at the pricey end of its own range (76th percentile), against a long-run median of 45.9× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

The price move, decomposed: over 5y, of the −11.0%/yr price move, ~−11.8%/yr came from earnings growth and ~+0.8 pp from the multiple (roughly flat); over 10y, of the +3.2%/yr price move, ~−2.9%/yr came from earnings growth and ~+6.1 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Camlin Fine Sciences Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

22.7/100 — rank 4 of 4 in Chemicals - Others · 88% evidence confidence

Camlin Fine Sciences Ltd scores 22.7 out of 100 against the 4 companies it is compared with in Chemicals - Others, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 6.4 + 4.7 + 5.6 + 6 = 22.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Camlin Fine Sciences Ltd reported ₹425 Cr of revenue in the Mar 26 quarter, −1.6% year on year. Over 10 years it has compounded at 13.4% a year. The last full year, FY26, came in at ₹1,723 Cr. The last four reported quarters add to ₹1,750 Cr.

Camlin Fine Sciences Ltd reported ₹425 Cr of revenue in the Mar 26 quarter, −1.6% year on year. Over 10 years it has compounded at 13.4% a year. The last full year, FY26, came in at ₹1,723 Cr. The last four reported quarters add to ₹1,750 Cr.

FY26 revenue came in at ₹1,723 Cr (+5.8% on the year), capping 10 years at 13.4% compound. The latest quarter (Mar 26) printed ₹425 Cr, −1.6% year on year.

Pace check: the last four quarters averaged +5.6% growth against the decade's 13.4% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +5.4% over the last 4 quarters against +4.9%/yr over the last 8 — stabilising.

→ Revenue slipped — did margins hold as it scaled? Next: 5.0% this quarter (−9.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Camlin Fine Sciences Ltd's operating margin is 5.0% in the Mar 26 quarter, −9.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 2.0% to 19.0%. The current quarter sits inside that band.

Camlin Fine Sciences Ltd's operating margin is 5.0% in the Mar 26 quarter, −9.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 2.0% to 19.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 5.0%, −9.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 2.0%–19.0%.

🚨 Why the margin moved: operating margin went −9.4 pp year on year while gross margin went −2.7 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

→ Margins slipped — did that reach the bottom line? Next: profit null in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Camlin Fine Sciences Ltd earned ₹86.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹24.0 Cr. The 10-year compound rate is −4.0%. That is 20.2% of the quarter's revenue. The same quarter a year earlier earned ₹0.0 Cr. 9 of the last 12 reported quarters were loss-making.

Camlin Fine Sciences Ltd earned ₹86.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹24.0 Cr. The 10-year compound rate is −4.0%. That is 20.2% of the quarter's revenue. The same quarter a year earlier earned ₹0.0 Cr. 9 of the last 12 reported quarters were loss-making.

Mar 26 profit was ₹86.0 Cr, null year on year. On the full year, FY26 printed ₹24.0 Cr (null), and the 10-year compound rate is −4.0%.

→ Profit rose — but did the cash follow? Next: 224% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 224% of Camlin Fine Sciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹82.0 Cr of operating cash against ₹24.0 Cr of profit. After ₹277 Cr of capital spending, ₹−195 Cr was left as free cash.

FY26: operating cash of ₹82.0 Cr against reported profit of ₹24.0 Cr, leaving free cash of ₹−195 Cr after ₹277 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 224% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 224%: the cash cycle tightened 106 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

→ So follow the cash to where it goes. Next: a 78-day cycle and ₹207 Cr of building.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Camlin Fine Sciences Ltd's cash conversion cycle runs 78 days in FY26, down from 184 days in FY21. Capital spending ran ₹207 Cr over the last 3 years. At FY26 sales of ₹1,723 Cr each day of that cycle holds about ₹4.7 Cr, so roughly ₹368 Cr sits inside the business at any moment.

FY26: debtors at 79 days, inventory at 199 days — roughly 6.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 78 days, tighter than FY21's 184.

The full loop: cash goes out to suppliers and production on day 0; stock waits 199 days to sell; customers pay about 79 days after that; and suppliers themselves are paid at 200 days — netting out to the 78-day cycle.

In money terms: at FY26 sales of ₹1,723 Cr, each day of the cycle holds about ₹4.7 Cr — so the 78-day loop keeps roughly ₹368 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹207 Cr over the last 3 fiscal years against ₹188 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹33.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 5% and the ROIC − WACC spread is −9.5 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Camlin Fine Sciences Ltd earns a ROCE of 5% in FY26. That is up from a trough of 0% in FY18. Return on invested capital clears the cost of that capital by −9.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.4% net margin on 0.74× asset turns.

FY26 ROCE is 5%, recovered from a FY18 trough of 0% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 1.4% net margin × 0.74× asset turns × 2.23× balance-sheet leverage ≈ 2.3% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 2.5% − 12.0% = a −9.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.69.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Camlin Fine Sciences Ltd carries total debt of ₹720 Cr against shareholder equity of ₹1,001 Cr as of Mar 26, a debt-to-equity of 0.72. On the annual view that ratio went from 0.84 in FY22 to 0.72 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Mar 26: total debt of ₹720 Cr against shareholder equity of ₹1,001 Cr — a debt-to-equity of 0.72. On the annual view, debt-to-equity went from 0.84 (FY22) to 0.72 (FY26). Read the returns on this page with that leverage in mind.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Camlin Fine Sciences Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved −0.1 points over the same window, to 0.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +0.5 points over 8 quarters to 5.4%; Foreign institutions: −0.1 points over 8 quarters to 0.9%; Promoters: +0.0 points over 8 quarters to 48.0%.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Camlin Fine Sciences Ltd: the Z-score reads 2.70. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 2.70 sits in the grey band — neither clearly safe nor clearly distressed.

The safety line in one sentence: the Z-score reads 2.70.

Frequently asked questions